Response and resistance in 300 patients with BCR‐ABL–positive leukemias treated with imatinib in a single center

Abstract

The data emphasized the need for a prolonged follow-up of patients treated with imatinib to define the clinical potential of the drug and to establish methods to optimize therapy.